FIELD: medicine.
SUBSTANCE: invention relates to a compound having a structure corresponding to the formula (I) or to its pharmaceutically acceptable salt, where R1 is phenyl optionally substituted with one or two F or pyridinyl; R2 is C1-C6 alkoxy or C3-C6 cycloalkoxy; R3 is hydrogen or -CH2-X; R4 and R5 are independently hydrogen, -OH, -OR, -N(R)(R), -CH2OH, -CH2OR, or -CH2N(R)(R), or R4 and R5 can form together dioxin, and at least one of R4 and R5 is not hydrogen; R6 and R7 are independently hydrogen; and z1-z8 are independently CH; where -X in each case is independently selected from -OH or -N(R)(R); and R in each case is independently optionally substituted C1-C12 alkyl. The invention also relates to a pharmaceutical composition based on a compound of the formula (I).
EFFECT: new compounds and a pharmaceutical composition based on them are obtained, which can be used in medicine for the treatment and prevention of a parasitic disease, which is malaria or cryptosporidiosis.
61 cl, 5 tbl, 52 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | 2015 |
|
RU2733756C2 |
| RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | 2016 |
|
RU2697703C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
| COMPOUNDS AND METHODS FOR ENHANCING DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES, USING E3 UBIQUITIN LIGASE | 2013 |
|
RU2781452C2 |
| PYRAZOLOPYRIMIDINE-BASED JAK INHIBITING COMPOUNDS AND METHODS | 2010 |
|
RU2567238C2 |
| INHIBITING JAK COMPOUNDS BASED ON PYRAZOLOPYRIMIDINE AND METHODS | 2010 |
|
RU2675857C2 |
| IMIDAZOPIRASOTHINES AS PDE1 INHIBITORS | 2016 |
|
RU2712219C2 |
| BICYCLIC DIHYDROPYRIMIDINECARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 2017 |
|
RU2778478C2 |
| ORGANIC COMPOUNDS | 2019 |
|
RU2809023C2 |
| PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF | 2016 |
|
RU2735522C2 |
